**** I took this from an excellent contributor on the PTX forum (with thanks), but it’s obviously very telling that a pre-clinical asset can be bought out for almost 50% more than our current market cap, which of course includes $60m cash) ****
Roche has acquired Good Therapeutics US$250m (A$370m) cash and the biotech's shareholders will also be eligible for future (undisclosed) development, regulatory and commercial milestone payments.
Good Therapeutics has progressed from inception 6 years ago with venture capital backing of just US$30m.
The focus of Roche’s acquisition of Good Therapeutics is the biotech’s most advanced project, a preclinical cancer therapy designed to make the multiple current PD-1 targeting cancer therapeutics, such as Keytruda and Opdivo, benefit more patients. Its therapy is designed to deliver potent IL-2 stimulation of T cells without the toxicity that can limit unregulated IL-2 therapeutics.
https://www.statnews.com/2022/09/07...-preclinical-cancer-therapy/?utm_campaign=rss
https://www.fiercebiotech.com/biote...hape-shifting-program-250m-skys-limit-spinout
**** I took this from an excellent contributor on the PTX forum...
-
- There are more pages in this discussion • 1,832 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |